# Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

> **NCT02071888** · PHASE1 · COMPLETED · sponsor: **Calithera Biosciences, Inc** · enrollment: 25 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma (NHL)
- Multiple Myeloma
- Waldenstrom's Macroglobulinemia (WM)
- Other B-cell NHL Subtypes, Including WM
- T-cell NHL

## Interventions

- **DRUG:** CB-839
- **DRUG:** CB-839 and low dose dexamethasone
- **DRUG:** CB-839, pomalidomide, and low dose dexamethasone

## Key facts

- **NCT ID:** NCT02071888
- **Lead sponsor:** Calithera Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2018-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02071888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02071888, "Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02071888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*